Cyxtera Results Presentation Deck

Transaction Adjusted EBITDA Bridge: Q1 2021 to Q1 2022 ($ in Millions) Cyxtera (1) (2) $56.1 Q1'21 +$9.5 Change in Revenue + $0.3 Change in Cost of Revenue (2) -$3.7 Change in SG&A -$3.7 Change in Adjustments (1) (2) $58.6 Q1'22 Includes pro form a EBITDA adjustments related to one-time stand-up costs, recurring expenses, restructuring & cost-savings initiatives, as well as product development & start-up costs. Excludes the impact of $11.8M benefit related to change in fair value of derivative liabilities, offset by $1.4M in restructuring, impairment, site closures and related cost in Q1 22 and $8.1M in restructuring, impairment, site closures and related cost in Q1 21 15

View entire presentation